Retatrutide peptide: what the name means and what the data shows

Last updated 2026-07-25

What is retatrutide peptide, exactly?

Retatrutide is a synthetic peptide drug candidate that activates three separate hormone receptors at once: GIP, GLP-1, and glucagon. That's the whole story behind the term "triple agonist," and it's what separates retatrutide from older incretin drugs. Semaglutide (Ozempic, Wegovy) hits only the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) hits GIP and GLP-1. Retatrutide adds a third target, the glucagon receptor, which is thought to add extra energy expenditure on top of the appetite suppression the other two receptors drive ^[1]. Its development code is LY3437943, and that's the identifier you'll see on the actual clinical trial registrations. "Retatrutide" is the generic name Eli Lilly assigned once the compound moved into the naming process, but it has never received an FDA-approved brand name because it has never been approved for anything ^[2]. So when someone searches "reta peptide" or "peptide retatrutide," they're looking at the same molecule under different shorthand. There's no separate "peptide version" that's somehow different or more accessible than the drug studied in trials. It's one compound, one molecule, tested under one development program.

Is retatrutide FDA approved?

No. A direct query of Drugs@FDA, the FDA's own database of every approved drug product in the country, returns zero results for the generic name retatrutide ^[2]. There is no approved indication, no approved dose, no approved label, nothing. That matters more than it sounds like it should, because plenty of gray-market sellers imply approval is just a formality or already underway. It isn't a formality. Under 21 U.S.C. 355, a new drug cannot be introduced into interstate commerce without an approved application ^[3]. That's the actual legal basis for why retatrutide isn't sitting on a pharmacy shelf next to Zepbound. It's still in the trial pipeline, and federal law treats it as an unapproved new drug until that changes. For comparison, orforglipron, an oral GLP-1 drug, was approved under NDA 220934 as FOUNDAYO in six strengths from 0.8 mg to 17.2 mg ^[4]. That approval shows what the finish line actually looks like: a real NDA number, real approved strengths, a real product name. Retatrutide has none of that yet.

What does the phase 2 trial data actually show?

The headline number is real and it's a big one. In the published phase 2 obesity trial, the 12 mg dose of retatrutide produced a mean weight reduction of 24.2 percent at 48 weeks, compared with 2.1 percent for placebo ^[5]. Dosing was once-weekly subcutaneous injection, titrated up over several weeks rather than started at full dose. That trial is registered publicly as NCT04881760, "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight" ^[6]. The registration lists the dose arms actually tested and the route of administration, which is worth checking yourself if you want the primary source rather than someone's summary of it. Retatrutide has moved past phase 2. Later-phase trials are registered as NCT05929066 ^[7] and NCT05882045 ^[2], and those records list current enrollment criteria, comparator arms, and endpoints. It's also been studied in registered type 2 diabetes trials, more than obesity, so the evidence base isn't limited to one condition ^[7]. None of this changes the approval status. Phase 2 and phase 3 data, even data as strong as 24.2 percent weight loss, doesn't put a drug on the market. It's evidence a drug might eventually get approved, not proof it's currently legal to prescribe, compound, or sell.

Why can't a compounding pharmacy legally make retatrutide?

This is where most of the confusion around "reta peptides" and gray-market listings actually lives, so it's worth walking through the mechanics. Section 503A of the FD&C Act lets compounding pharmacies make drugs from bulk substances, but only through a strict cascade. First, the substance has to comply with an applicable USP or National Formulary monograph, if one exists. If no monograph exists, it has to be a component of an FDA-approved drug. Only if neither of those applies can it come from the 503A Bulks List, a specific list FDA maintains ^[1]. Retatrutide satisfies none of the three. No monograph. Not a component of any approved drug, because there is no approved drug. And it is not on the Bulks List. The complete 503A Bulks List, codified at 21 CFR 216.23, contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[8]. No peptide is on that list at all, let alone retatrutide. For context on how substances even get considered, FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to weigh seven different peptides for possible addition to the Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[9]. Retatrutide wasn't among them and has never been nominated for that list at all ^[9]. And even if it had gotten a favorable vote, that alone wouldn't create a pathway. Advisory committee recommendations are non-binding, and actually adding something to the Bulks List requires full notice-and-comment rulemaking ^[9], which takes years, not months. There's a separate, parallel list for 503B outsourcing facilities, at 21 CFR 216.24, and retatrutide isn't on that one either ^[10]. So there is genuinely no lawful compounding pathway on either side of the system right now.

There's also a second, independent legal barrier

Even setting the ingredient cascade aside entirely, 503A has a completely separate requirement: every bulk drug substance used has to come from an establishment registered under FD&C Act section 510, and it has to be accompanied by a valid certificate of analysis ^[1]. This is the part that trips up a lot of "research use only" material sold online. Even if retatrutide somehow qualified under the ingredient cascade (it doesn't), material sourced from an unregistered supplier with no real certificate of analysis fails this second requirement on its own. Two independent legal failures, either one of which is enough by itself to make lawful compounding impossible right now.

What does 'research use only' actually mean on these sites, and is it legal?

It usually means nothing legally, and FDA has said so directly. A disclaimer that a product is "not for human consumption" or "for research use only" does not defeat drug status if the seller's marketing establishes a therapeutic intent. In a March 2026 warning letter to a company called Gram Peptides, FDA wrote that despite RUO-style labeling, "evidence from the company's website established that its products were intended to be drugs for human use," and the letter specifically named retatrutide as one of the products marketed on that site ^[9]. That's about as direct as FDA gets on this exact question. The legal mechanism behind that is 21 CFR 201.128, FDA's regulation defining "intended use." It states that intended use is established by labeling claims, advertising matter, or oral or written statements made by the seller ^[4]. So it's the marketing copy, not the disclaimer, that determines whether a product is legally a drug. If a site sells retatrutide alongside language about fat loss, appetite suppression, or metabolic health, that language is the evidence FDA uses, and the RUO label doesn't erase it. So if you see "aavant research retatrutide" or similar vendor listings framed as research chemicals, understand that the RUO label is not a legal shield. It's marketing language sitting next to a product that, under FDA's own stated reasoning, may already look like an unapproved drug regardless of what the label says.

Can I legally import retatrutide from overseas myself?

FDA has a published personal importation policy, and it's the actual rule that would apply to anyone ordering an investigational compound from a foreign site . The short version is that FDA generally does not permit importation of unapproved drugs for personal use, though it has historically exercised discretion in narrow situations involving serious conditions with no US treatment available and no known safety risk, and even then only in small amounts. Retatrutide doesn't fit the profile that policy was written for. It's not a drug with no domestic equivalent for a serious untreated condition. There are approved, marketed options in the same drug class (more on that below), and importing an unapproved injectable peptide from an unverified overseas source carries its own risks around purity, dosing accuracy, and contamination that the FDA policy doesn't waive. Practically: ordering retatrutide from an overseas RUO seller is not a lawful workaround to the compounding restrictions described above. It's a separate legal exposure, and a separate safety risk, layered on top of the same underlying problem: no approved product exists yet.

What legal alternatives exist right now?

If you're looking at retatrutide because you want a triple-agonist-level result, there currently isn't a lawful equivalent, because nothing else on the market hits all three receptors. But there are FDA-approved options in the same general drug family that a clinician can actually prescribe today. Semaglutide is approved and marketed as Ozempic and Wegovy. Tirzepatide is approved as Mounjaro and Zepbound. Orforglipron, an oral option, was approved as FOUNDAYO under NDA 220934 ^{[11] [4]}. These all have published safety data, approved labeling, and real prescribing pathways through a licensed physician. They're not retatrutide, and none of them will replicate a 24.2 percent trial result from a different molecule at a different dose. But they're real, obtainable, and monitored, which an RUO vial from an unregistered supplier is not. For readers weighing options while retatrutide remains investigational, NIDDK publishes federal guidance on evidence-based weight management that's a reasonable neutral starting point for the conversation with a clinician . If you want the mechanics of how retatrutide trials actually dosed the drug, we cover that in detail on our retatrutide dosage chart, though none of that is a self-administration protocol; it's a report of what trials used.

How does retatrutide compare to semaglutide and tirzepatide mechanistically?

The receptor count is the real difference. Semaglutide is a single agonist, hitting only GLP-1. Tirzepatide is a dual agonist, hitting GIP and GLP-1. Retatrutide is a triple agonist, adding the glucagon receptor on top of both ^[5]. The theory behind adding a third receptor is that glucagon receptor activation increases energy expenditure, which is a different mechanism from appetite suppression alone. Whether that translates into a durable real-world advantage outside of a 48-week phase 2 trial is still an open question; phase 3 data will be the real test, and that's exactly what NCT05929066 and NCT05882045 are set up to answer ^{[7] [2]}. | Drug | Receptors targeted | FDA status | Reported trial result |

What is the retatrutide peptide name I'll see on research sites?

You'll see a handful of names used interchangeably, and it's worth knowing they all point to the same molecule. "Retatrutide" is the assigned generic name. "LY3437943" is Eli Lilly's development code and the identifier actually used on ClinicalTrials.gov registrations ^{[6] [7] [2]}. Some vendor sites shorten it to "reta" or list it as "reta peptide" or "peptides retatrutide." None of these are different products. There's no separate research-grade formulation that's legally distinct from the clinical compound. If a site is selling something labeled with any of these names for human use, the same regulatory analysis in the sections above applies regardless of which name is on the label.

What happens if I take retatrutide from an unregulated source anyway?

You're taking on risks that have nothing to do with the drug's underlying trial data. Material from an unregistered supplier, without a valid certificate of analysis, has no verified purity, concentration, or sterility guarantee ^[1]. That's a distinct problem from whether the molecule itself works; a phase 2 trial testing pharmaceutical-grade retatrutide under clinical supervision tells you nothing about what's actually in a vial from an unverified seller. There's also no clinician oversight. Trial participants in NCT04881760 were monitored for adverse events under a controlled protocol ^[6]. Someone self-administering from a gray-market source has no equivalent safety net, no baseline labs, no dose titration overseen by a physician, and no clear route to report or manage an adverse reaction. If you want a full breakdown of the reported side effect profile from the actual trial data, see our retatrutide side effects page; that's the honest accounting of what's been observed under supervision, which is a different risk category than unsupervised use of unverified material.

Frequently asked questions

What is retatrutide peptide?

Retatrutide is an investigational peptide drug that activates GIP, GLP-1, and glucagon receptors at once. Its development code is LY3437943. It has shown a 24.2% mean weight reduction at 48 weeks in a phase 2 trial at the 12 mg dose, but it has no FDA approval and no lawful path to prescription or compounding in the US right now.

Is retatrutide FDA approved yet?

No. A search of Drugs@FDA for the generic name retatrutide returns no approved product. It remains in clinical trials, including later-phase studies registered as NCT05929066 and NCT05882045, and it cannot lawfully be introduced into interstate commerce as a drug under 21 U.S.C. 355 until an application is approved.

Can a compounding pharmacy legally make retatrutide?

No. Section 503A requires a bulk substance to meet a USP/NF monograph, or be a component of an approved drug, or appear on the 503A Bulks List. Retatrutide meets none of those three conditions, and the Bulks List at 21 CFR 216.23 contains only six substances, none of them a peptide.

What is the retatrutide peptide name shown on research-use-only sites?

Most RUO sites use either "retatrutide" (the generic name) or "LY3437943" (Eli Lilly's development code), sometimes shortened to "reta." These all refer to the same molecule studied in trials; there's no separate research-grade version that's legally distinct from the clinical compound.

Does a 'research use only' label make retatrutide legal to sell?

Not by itself. FDA's own regulation on intended use, 21 CFR 201.128, says drug status is established by labeling claims and advertising, not disclaimers. A March 2026 FDA warning letter to Gram Peptides found the company's website established therapeutic intent for retatrutide despite RUO labeling, so the disclaimer didn't change its legal status.

How much weight loss did retatrutide show in trials?

In the published phase 2 obesity trial, the 12 mg weekly dose produced a mean 24.2% weight reduction at 48 weeks, compared to 2.1% with placebo. That's from Jastreboff et al., New England Journal of Medicine, 2023, and reflects a supervised trial population, not real-world unsupervised use.

How is retatrutide different from tirzepatide and semaglutide?

Retatrutide is a triple agonist, activating GIP, GLP-1, and glucagon receptors. Tirzepatide (Mounjaro, Zepbound) hits two of those (GIP and GLP-1). Semaglutide (Ozempic, Wegovy) hits only GLP-1. The added glucagon receptor activity is thought to raise energy expenditure beyond appetite suppression alone, though phase 3 data will be the real test of that.

Can I legally import retatrutide for personal use?

FDA's personal importation policy generally does not permit bringing in unapproved drugs for personal use, and retatrutide doesn't fit the narrow discretionary cases FDA has historically allowed, since approved alternatives already exist in the same drug class. Importing it from an overseas RUO seller is not a lawful workaround.

Was retatrutide considered for the FDA compounding Bulks List?

No. FDA's Pharmacy Compounding Advisory Committee met in July 2026 to weigh seven different peptides (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon) for the 503A Bulks List. Retatrutide wasn't among them and has never been nominated for that list.

What legal alternatives exist to retatrutide right now?

FDA-approved incretin drugs currently on the market include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and orforglipron (FOUNDAYO, an oral option approved under NDA 220934). None replicate retatrutide's triple-receptor mechanism, but all are prescribable today with published safety data.

What trials is retatrutide currently being studied in?

Retatrutide has a registered phase 2 obesity trial (NCT04881760) and later-phase trials registered as NCT05929066 and NCT05882045, plus registered type 2 diabetes trials. These records list current enrollment criteria, comparator arms, and dosing under study.

Is buying retatrutide peptides online safe or legal?

It's neither guaranteed safe nor clearly legal. Material from unregistered suppliers lacks a valid certificate of analysis required under 503A, meaning no verified purity or sterility. FDA has already issued a warning letter over retatrutide marketing despite RUO disclaimers, and self-administering unverified material carries risks with no clinical oversight.

Sources

1. 21 U.S.C. 353a(b)(1)(A)(ii)-(iii), Cornell Legal Information Institute: 503A requires bulk substances to come from an FD&C Act section 510 registered establishment with a valid certificate of analysis, separate from the ingredient cascade requirement
2. Drugs@FDA, FDA-approved drug products database: A query for the generic name retatrutide returns no FDA-approved product
3. Jastreboff AM et al., New England Journal of Medicine, 2023: Retatrutide 12 mg produced 24.2% mean weight reduction at 48 weeks vs 2.1% placebo, and it acts as a triple GIP/GLP-1/glucagon receptor agonist
4. ClinicalTrials.gov, NCT04881760: Registration record for the phase 2 retatrutide obesity trial, listing dose arms, route, and development code LY3437943
5. 21 CFR 216.23, eCFR: The complete 503A Bulks List contains exactly six substances, none of them retatrutide or any peptide
6. Drugs@FDA, NDA 220934 (orforglipron/FOUNDAYO): Orforglipron was approved as FOUNDAYO in six strengths from 0.8 mg to 17.2 mg, and 21 CFR 201.128 defines intended use via labeling and advertising rather than disclaimers
7. 21 U.S.C. 355, Cornell Legal Information Institute: A new drug cannot be introduced into interstate commerce without an FDA-approved application
8. ClinicalTrials.gov, NCT05929066: Later-phase retatrutide trial registration listing enrollment criteria, comparators, and endpoints, including type 2 diabetes study population
9. ClinicalTrials.gov, NCT05882045: Second later-phase retatrutide trial registration confirming dosing and design under study
10. 21 CFR 216.24, eCFR: The separate 503B outsourcing facility bulks list also does not include retatrutide
11. FDA, Personal Importation policy: FDA's personal importation policy generally restricts bringing unapproved drugs into the US for personal use
12. NIDDK, Weight Management: NIDDK publishes federal guidance on evidence-based weight management as a neutral reference point